drugset / Trial / NCT00632424
Phase 1 Trial of Oral Ixabepilone
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer
Timeline
- Start
- 2008-05
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | — | Oral |